{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:14:00Z","timestamp":1761894840875,"version":"3.38.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Womens Health (Lond Engl)"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:p> Denosumab is an investigational fully human monoclonal antibody to RANKL, a cytokine member of the tumor necrosis factor family that is the principal mediator of osteoclastic bone resorption. RANKL stimulates the differentiation, activity and survival of osteoclasts, and is implicated in the pathogenesis of postmenopausal osteoporosis and other skeletal disorders associated with high rates of bone remodeling. By inhibiting the action of RANKL, denosumab reduces the differentiation, activation and survival of osteoclasts and slows the rate of bone resorption. Postmenopausal women with low bone mineral density treated with denosumab have an increase in bone mineral density and a reduction of bone turnover markers that is rapid, sustained and reversible. In postmenopausal women with osteoporosis, denosumab reduces the risk of vertebral, hip and nonvertebral fractures. Denosumab is well tolerated with a favorable safety profile. <\/jats:p>","DOI":"10.2217\/17455057.5.1.15","type":"journal-article","created":{"date-parts":[[2009,1,16]],"date-time":"2009-01-16T16:54:19Z","timestamp":1232124859000},"page":"15-22","source":"Crossref","is-referenced-by-count":5,"title":["Denosumab for the Treatment of Postmenopausal Osteoporosis"],"prefix":"10.1177","volume":"5","author":[{"given":"E Michael","family":"Lewiecki","sequence":"first","affiliation":[{"name":"E Michael Lewiecki New Mexico Clinical Research & Osteoporosis Center, 300 Oak St NE, Albuquerque, New Mexico, NM 87106, USA, Tel.: +1 505 855 5525, Fax: +1 505 884 4006,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,1,1]]},"reference":[{"key":"bibr00101-17455057.5.1.15","unstructured":"Papers of special note have been highlighted as:"},{"key":"bibr00102-17455057.5.1.15","unstructured":"of interest"},{"key":"bibr00103-17455057.5.1.15","unstructured":"of considerable interest"},{"key":"bibr1-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.6.785"},{"key":"bibr2-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)90022-X"},{"key":"bibr3-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1514-0"},{"key":"bibr4-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.18.2165"},{"key":"bibr5-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1502-4"},{"key":"bibr6-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1652-z"},{"key":"bibr7-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2004.02.005"},{"volume-title":"Bone Health and Osteoporosis: a report of the Surgeon General","year":"2004","author":"US Department of Health and Human Services","key":"bibr8-17455057.5.1.15"},{"volume-title":"Assessment of osteoporosis at the primary health-care level","year":"2007","author":"Kanis JA","key":"bibr9-17455057.5.1.15"},{"key":"bibr10-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0550-6"},{"key":"bibr11-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-008-0559-5"},{"volume-title":"Clinician's Guide to Prevention and Treatment of Osteoporosis","year":"2008","author":"National Osteoporosis Foundation","key":"bibr12-17455057.5.1.15"},{"volume-title":"Physician's Guide to Prevention and Treatment of Osteoporosis","year":"2003","author":"National Osteoporosis Foundation","key":"bibr13-17455057.5.1.15"},{"key":"bibr14-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040305"},{"key":"bibr15-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070809"},{"key":"bibr16-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044459"},{"key":"bibr17-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.04.007"},{"key":"bibr18-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2814"},{"key":"bibr1022-17455057.5.1.15","unstructured":"This Phase III study of denosumab versus placebo for the prevention of postmenopausal osteoporosis (PMO) validates the findings of earlier studies that showed an increase in bone mineral density (BMD) and reduction of bone turnover markers in postmenopausal women with low BMD."},{"key":"bibr19-17455057.5.1.15","first-page":"S80","volume":"23","author":"Cummings SR","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"bibr20-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.2217\/17455057.2.4.517"},{"key":"bibr21-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.041114"},{"key":"bibr22-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(95)00502-1"},{"key":"bibr23-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.15.1762"},{"issue":"5","key":"bibr24-17455057.5.1.15","first-page":"2060","volume":"87","author":"Meunier PJ","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"bibr25-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.12.020"},{"key":"bibr26-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1038\/nature01658"},{"key":"bibr27-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000149165.99974.12"},{"key":"bibr28-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"bibr29-17455057.5.1.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.4.490"},{"key":"bibr30-17455057.5.1.15","first-page":"S293","volume":"20","author":"Peterson MC","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"bibr31-17455057.5.1.15","doi-asserted-by":"crossref","unstructured":"Brown JP, Prince RL, Deal C, Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, Phase 3 trial. J. Bone Miner. Res. DOI: 10.1359\/jbmr.080910 (2008) (Epub ahead of print).","DOI":"10.1359\/jbmr.080910"},{"key":"bibr1036-17455057.5.1.15","unstructured":"Head-to-head trial of denosumab versus alendronate demonstrated a greater increase in BMD and a greater reduction of bone turnover markers with denosumab."},{"key":"bibr32-17455057.5.1.15","first-page":"S473","volume":"23","author":"Kendler DL","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"bibr101-17455057.5.1.15","unstructured":"International Osteoporosis Foundation: IOF Osteoporosis Teaching Slide Kit. www.osteofound.org\/health_professionals\/teaching_resources\/slide_kit.html (Accessed March 26, 2006)."},{"key":"bibr102-17455057.5.1.15","unstructured":"Amgen Inc: Form 8-K. http:\/\/investors.amgen.com\/phoenix.zhtml?c=61656&p=irol-sec (Accessed September 16, 2008)."},{"key":"bibr103-17455057.5.1.15","unstructured":"Pending the publication of FREEDOM data in a peer-reviewed journal, this is the most detailed authoritative document on fracture risk reduction and safety end points with denosumab versus placebo in women with PMO."}],"container-title":["Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.5.1.15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2217\/17455057.5.1.15","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.5.1.15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T07:42:35Z","timestamp":1741678955000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2217\/17455057.5.1.15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.2217\/17455057.5.1.15"],"URL":"https:\/\/doi.org\/10.2217\/17455057.5.1.15","relation":{},"ISSN":["1745-5057","1745-5065"],"issn-type":[{"type":"print","value":"1745-5057"},{"type":"electronic","value":"1745-5065"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}